参考文献/References:
[1] Couturier 0,Luxen A,Chatal JF,et al.Fluorinated tracers for imaging cancer with positron emission tomography[J].Eur J Nucl Med Mol Imaging,2004,31(8):1182-1206.
[2] Yamaura G, Yoshioka T, Fukuda H,et al.O-18F-fluoromethyl-Ltyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET:an initial comparative in vivo study with deoxyglucose and thymidine[J].Eur J Nucl Med Mol Imaging, 2006,33(10):1134-1139.
[3] Prante 0,Bläser D Masehauer S,et al.In vitro characterizatlon of the thyroidal uptake of O-(2-18F-fluoroethyl)-L-tyrosine[J].Nucl Med Biol,2007,34(3):305-314.
[4] Weckesser M,Langen KJ,Rickert CH,et al,O-(2-18F-fluorethyl)-Ltyrosine PET in the clinical evaluation of primary brain tumoursIJ]. Ear J Nucl Med Mol Imaging.2005,32(4):422-429.
[5] Pöpperl G,Götz C,Rachinger W,et al.Value of O-(2-18F-fluoroethyl)-I-tyrosine PET for the diagnosis of recurrent glioma[J]. Eur J Nucl Med Mol Imaging,2004,31(11):1464-1470.
[6] Mehrkens JH,Pöpperl G,Rachinger W,et al.The positive predictive value of O-[218F-fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence[J].J Neurooncol,2008,88(1): 27-35.
[7] Floeth FW,Pauleit D,Sabel M,et al.18F-FET PET differentiation of ring-enhancing brain lesions[J].J Nucl Med,2006,47(5):776-782.
[8] Tang G,Wang M,Tang X,et al.Synthesis and evaluation of O-(3-18F-fluoropropyl)-L-tyrosine as an oncologic PET tracer[J].Nucl Med Bid,2003,30(7):733-739.
[9] Moon BS,Lee TS,Lee KC,et al.Syntheses of 18F. fluoroalkyltyrosine derivatives and their biological evaluation in rat bearing 9L tumor[J].Bioorg Med Chem Lett,2007,17(1):200-204.
[10] Tsukada H,Sato K, Fukumoto D,et al.Evaluation of D-isomers of O-18F-fluoromethyl,O-18F-fluoroethyl and O-18F-fluoropropyl tyrosine as tumour imaging agents in mice[J].Eur J Nucl Med Mol Imaging,2006,33(9):1017-1024.
[11] Seibyl JP,Chen W,Silverman DH.3,4-dihydmxy-6-18F-fluoro-L-phenylalanine positron emission tomography in patients with central motor dimrders and in evaluation of brain and other tumors[J].Semin Nucl Med,2007,37(6):440-450.
[12] Kersemans K,Bauwens M,Mertens J.Method for stabilizing non carrier added 2-18F-fluoromethyl-L-phenylalanine.a new tumour tracer,during radiosynthesis and radiopharmaceutieal formulation[J].Nucl Med Biol,2008,35(4):425-432.
[13] Chen W,Silverman DH,Delaloye S,et al.18F-FDOPA PET imaging of brain tumors:comparison study with 18F-FDG PET and evaluation of diagnostic accuracy[J].J Nucl Med,2006,47(6):904-911.
[14] Beuthien-Baumann B,Bredow J,Burehert W,et al.3-O-Methyl-6-18F-fluoro-L-DOPA and its evaluation in brain tumour imaging[J]. Eur J Nuel Med Mol Imaging,2003,30(7):1004-1008.
[15] Haase C,Bergmann R,Fuechtner F,et al.L-type amino acid transporters LATl and LAT4 in cancer.uptake of 3-O-methyl-6-18F-fluoro-L-dopa in human adenecareinoma and squarnous cell carcinoma in vitro and in vivo[J].J Nucl Med,2007,48(12):2063-2071.
[16] Langen KJ,Jarosch M,Hamacher K,et al.Imaging of gliomas with Cis-418F-fluoro-L-proline[J].Nucl Med Biol,2004,3l (1):67-75.
[17] Langen KJ,Mühlensiepon H,Schmieder S,et al.Transport of cis- and tmns-4-18F-fluoro-L-proline in F98 glioma cells[J].Nucl Med Biol,2002,29(6):685-692.
[18] Tang G,Wang M,Tang x,et al.Fully automated synthesis module for preparation of S-(2-18F-fluoroethyl)-L-methionine by direct nucleophilic exchange on aquaternary 4-aminopyfidinium resin[J]. Nucl Med Biol,2003,30(5):509-5l2.
[19] Nye JA,Schuster DM.Yu W,et al.Biodistribution and radiation dosimetry of the synthetic nonmetabelized amino acid analogue anti-18F-FACBC in humans[J].J Nucl Med,2007,48(6):1017-1020.
[20] Schuster DM,Votaw JR,Nieh PT,et al.Initial experience with the radiotracer anti-1-amino-3-18F-fluoroeyclobutane-1-carbexylic acid with PET/CT in prostate carcinoma[J].J Nucl Med,2007,48(1): 56-63.
相似文献/References:
[1]解朋,黄建敏,张芳,等.99Tcm-MAG3-isoDGR-2C分子探针的制备与体内分布的实验研究[J].国际放射医学核医学杂志,2016,40(5):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
Xie Peng,Huang Jianmin,Zhang Fang,et al.Labeling MAG3-isoDGR-2C with 99Tcm and its biodistribution in mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
[2]夏伟,吕中伟,王国玉,等.99Tcm标记depreotide及与肺腺癌A549细胞亲和性研究[J].国际放射医学核医学杂志,2010,34(4):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
XIA Wei,LÜ,Zhong-wei,et al.Experimental studies of depreotide labeled with 99Tcm and the affinity with human lung adenocarcinoma cell line A549[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):193.[doi:10.3760/cma.j.issn.1673-4114.2010.04.001]
[3]朱沭,赵明,陈璟.核酸及其类似物的常见放射性核素标记及显像[J].国际放射医学核医学杂志,2011,35(1):44.[doi:10.3760/cma.j.issn.1673-4114.2011.01.013]
ZHU Shu,ZHAO Ming,CHEN Jing.Radionuclide labeling and imaging nucleic acids and its analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):44.[doi:10.3760/cma.j.issn.1673-4114.2011.01.013]
[4]洪智慧,周小林,石怡珍,等.131I标记抗胃泌素释放前体单链抗体的制备及其稳定性和免疫活性研究[J].国际放射医学核医学杂志,2010,34(2):107.[doi:10.3760/cma.j.issn.1673-4114.2010.02.013]
HONG Zhi-hui,ZHOU Xiao-lin,SHI Yi-zhen,et al.Preparation and evaluation of 131I-anti-ProGRP(31-98) single-chain antibody fragment[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):107.[doi:10.3760/cma.j.issn.1673-4114.2010.02.013]
[5]刘键,张现忠,张仕坚,等.99Tcm标记双膦酸盐骨显像剂的研究进展[J].国际放射医学核医学杂志,2009,33(5):296.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.013]
LIU Jian,ZHA NG Xian-zhong,ZHA NG Shi-jian,et al.The new advanced of 99Tcm-labeled bisphosphonates as bone scintigraphy agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(4):296.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.013]
[6]李楠,李培勇.放射性碘间接标记抗体方法的研究进展[J].国际放射医学核医学杂志,2008,32(5):260.
LI Nan,LI Pei-yong.The recent development of the strategy for indirect antibody radiolabel with iodine[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(4):260.
[7]薛艳,安瑞芳,喻明启,等.99mTc标记抗β-人绒毛膜促性腺激素单克隆抗体[J].国际放射医学核医学杂志,2007,31(2):68.
XUE Yan,AN Rui-fang,YU Ming-qi,et al.Direct labeling of anti β-human chorionic gonadotropin monoclonal antibody with 99mTc[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):68.
[8]苏燕,王峰,王自正,等.131Ⅰ-Tyr-octreotide的标记方法学及其生物学分布的研究[J].国际放射医学核医学杂志,2007,31(5):257.
SU Yan,WANG Feng,WANG Zi-zheng,et al.abeling mothod and biodistribution of 131Ⅰ-Tyr-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):257.
[9]范光磊,吴翼伟,章斌.用99mTc标记胰岛素样生长因子1类似物的方法学研究[J].国际放射医学核医学杂志,2007,31(4):208.
FAN Guang-lei,WU Yi-wei,ZHANG Bin.Investigations of labeling insulin-like growth factor 1 analogue with 99mTc[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):208.
[10]冯彦林,谭家驹,梁生,等.[188Re(CO)3(H2O)3]+间接标记免疫磁性纳米微粒的实验研究[J].国际放射医学核医学杂志,2007,31(4):211.
FENG Yan-lin,TAN Jia-ju,LIANG Sheng,et al.Labeling of immuno-magnetic nanoparticle with[188Re(CO)3(H2O)3]+[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):211.